Medicare expands coverage for Personalis’ NeXT Personal minimal residual disease test, boosting potential U.S. market access.
Personalis (PSNL) shares climbed approximately 5% in premarket trading after securing its fourth Medicare coverage decision for NeXT Personal, a minimal residual disease test for cancer patients. The decision broadens reimbursement eligibility in the U.S., enhancing the test’s commercial prospects.
The company previously received three similar Medicare coverage decisions, signaling growing recognition of its diagnostic technology. NeXT Personal is designed to detect residual cancer cells post-treatment, a critical factor in patient monitoring and therapy decisions.
The announcement follows a press release from Personalis, which highlighted the expanded coverage as a key milestone for the test’s adoption among healthcare providers.